Blood Level Omega-3 Fatty Acids as Risk Determinant Molecular Biomarker for Prostate Cancer
Table 4
Blood level omega-3 polyunsaturated fatty acids versus high-grade prostate risk random effect analysis model.
Groups
Effect estimates and 95% confidence interval
Publication bias
Omega-3 derivatives
Number of study
value
df
value
Point estimates
Lower limit
Upper limit
value
Begg
Egger
ALA
5
7.731
4
0.102
48.264
0.965
0.605
1.538
0.881
0.807
0.870
DHA
5
8.593
4
0.072
53.449
1.233
0.769
1.978
0.385
0.221
0.051
DHA‡
4
4.310
3
0.230
30.389
1.462
0.972
2.199
0.068
0.734
0.265
DPA
3
3.291
2
0.193
39.231
0.597
0.299
1.193
0.144
1.000
0.930
EPA
5
8.362
4
0.079
52.162
1.130
0.717
1.781
0.599
0.221
0.273
EPA‡
4
3.931
3
0.269
23.675
1.317
0.910
1.908
0.145
0.734
0.952
(DHA + DPA + EPA)*
20.370
10
0.026
50.908
1.232
0.955
1.590
0.108
(DHA + EPA)*
8.498
7
0.291
17.629
1.381
1.050
1.817
0.021
Total omega-3*
29.708
15
0.013
49.508
1.165
0.931
1.457
0.181
Interstudy heterogeneity was tested by Cochrane’s (Chi2) at a significance level of and quantified by , where % is considered to be evidence of substantial heterogeneity and ≥75%, considerable heterogeneity. ‡Interstudy variation adjusted (heterogeneous study removed from the pool of effect estimates).
*Generated from adjusted total effect estimates from each PUFA random effect analysis.
